Combination treatment for advanced liver cancer with diabetes
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a four-drug combination (epalrestat, HAIC chemotherapy, donafenib, and tislelizumab) as a first treatment for patients with advanced liver cancer that cannot be removed by surgery, who also have diabetes. The goal is to shrink the cancer while managing nerve damage from diabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer (BCLC stage C) that cannot be surgically removed, confirmed by biopsy or imaging
- You have diabetes mellitus and symptoms of diabetic nerve damage that need treatment
- Your liver function is preserved (Child-Pugh grade A or B, meaning good enough to handle strong treatments)
- You are 18–80 years old and able to care for yourself with minimal help (ECOG score 0–1)
- You do not have severe heart disease, kidney failure, low blood platelets, or active infections
- You are not pregnant, nursing, or being treated for another type of cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of liver-directed chemotherapy, targeted therapy, and immunotherapy to shrink advanced liver cancer that has a blood clot in the portal vein (the main vein to the liver). The goal is to make the tumor removable by surgery.
This trial tests a combination of treatments—chemotherapy delivered through the liver artery (HAIC), a targeted drug (donafenib), and an immunotherapy (sintilimab)—given before and after surgery for liver cancer that has a high chance of coming back. The goal is to see if this approach can lower the risk of recurrence.
This trial tests a combination of three treatments for advanced liver cancer that cannot be removed by surgery: a targeted oral drug (Donafenib), an immunotherapy (Sintilimab), and a type of chemotherapy given directly into the liver artery. The goal is to see if this triple therapy works better than current options for people who have not had any prior cancer treatment.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
This trial tests a treatment given before surgery to shrink liver cancer and improve outcomes. It combines a liver-directed therapy (HAIC) with two oral drugs (lenvatinib and a PD-1 inhibitor) for people with intermediate-stage liver cancer that can be removed surgically.
Hear when a new Diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.